

Tripling out on COPD:

The texture of COPD trials

Cait O'Sullivan, PharmD 26 January 2019 Cait.OSullivan@ti.ubc.ca

disclosures	
	Island Health BC Provincial Academic Detailing (PAD) Service Funding: BC Ministry of Health
	Therapeutics Initiative University of British Columbia Funding: BC Ministry of Health
	no other financial conflicts of interest to declare





2014 Cochrane Systematic Review Tiotropium versus placebo Health Related Quality of Life (SGRQ scale 0 to 100) 2.89 point improvement ≥ 4 points 1 in 10 people ●●●●●●●● 2015 Cochrane Systematic Review Tiotropium plus LABA (2 inhalers) vs tiotropium Health Related Quality of Life (SGRQ scale 0 to 100) 1.34 point improvement SGRQ improvement ≥ 4 points 1 in 14 people ●●●●●● Global Initiative for Chronic Obstructive Lung Disease GOLD **2016** guidelines


Have you noticed a difference since starting this treatment?

Are you less breathless? Can you do more? Can you sleep better?

Is that change worthwhile to you?

https://goldcopd.org/

Global Initiative for Chronic GOLD 2018 guidelines	Obstructive Lung Disease	
for symptoms	to reduce exacerbations	
any branchadilator	LAMA	
any bronchodilator	LAMA	
LAMA or LABA	LAMA+LABA	
\checkmark	↓	
LAMA+LABA	ICS+LABA+LAMA	
	https://goldcopd.org/	



Counting, analysing and reporting exacerbations of COPD in randomised controlled trials

S D Aaron,¹ D Fergusson,¹ G B Marks,² S Suissa,⁴ K L Vandemheen,¹ S Doucette,¹ F Maltais,³ J F Bourbeau,⁴ R S Goldstein,⁵ M Balter,⁵ D O'Donnell,⁶ M FitzGerald,⁷ for the Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium

clinical trials have not been consistent in how they count, record or analyse COPD exacerbations and methodological errors in the assessment of COPD exacerbations may lead to biased or spurious results

exacerbations **COPD** clinical trials severe

leading to hospital admission moderate treated with antibiotics and/or systemic corticosteroids mild increase in short acting bronchodilator

AARON Thorax 2008;63:122-128

US FDA 2007 TORCH fluticasone + salmeterol (Advair Diskus)

"Now, we had a little more trouble "presence of two major symptoms with the exacerbation endpoint ... There was no definition of the exacerbation itself ... There were no required symptoms ... We are measuring medication delivered, which is objective, but the decision when and who to treat was entirely undefined and therefore subjective"

SPARK 2013

glycopyrronium + indacaterol

(dyspnoea, sputum volume, sputum purulence) for at least 2 consecutive days or a worsening of one major symptom together with an increase in any one minor symptom (sore throat, cold, fever without other cause, cough, wheeze) for at least 2 consecutive days"


http://www.fda.gov/ohrms/doc /dockets/ac/07/transcripts/2007-4274t1-index.pdf; WEDZICHA Lancet Respir Med 2013;1:199-209

SPARK 2013 (LAMA+LABA vs LAMA)				
2224 participants with \geq 1 exacerbation in previous year				
mean age 63; 25% women; 82% White; 38% current smokers				
trial duration: 1.2 years				
LAMA+LABA	LAMA		LAMA	
glycopyrronium + indacaterol	glycopyrronium		tiotropium	
ULTIBRO Breezhaler	SEEBRI Breezhaler		SPIRIVA HandiHaler	
moderate or severe exacerbations (annual rate)				
0.84	0.95 0.93			
glycopyrronium + indacaterol vs. glycopyrronium rate ratio 0.88 (95%CI 0.77 to 0.99) rate ratio 0.90 (0.79 to 1.02)				
\downarrow 0.11 exacerbation per year			(0.00 (0.00 1.02)	
severe exacerbations (annual rate)				
0.09	0.12		0.08	
annual rate of exacerbations = total number of exacerbations divided by total person years of follow up WEDZICHA Lancet Respir Med 2013;1:199-209				

glycopyrronium + indacaterol	glycopyrronium	tiotropium	
serious adverse events (ie, hospitalizations, disability, death)			
23%	24%	22%	
COPD worsening (most frequent serious adverse event)			
15%	16%	12%	

Global Initiative for Chronic Obstructive Lung Disease GOLD 2018 guidelines for symptoms to reduce exacerbations any bronchodilator LAMA ↓ ↓ LAMA or LABA LAMA+LABA ↓ ↓ LAMA+LABA ICS+LABA+LAMA https://goldcopd.org/


2016 Cochrane Systematic Reviews tiotropium plus ICS/LABA vs tiotropium alone (as 2 separate inhalers) The current evidence is <u>insufficient</u> to support the benefit of tiotropium + LABA/ICS-based therapy for mortality, hospital admission or exacerbations



IMPACT 2018 (triple vs. double combination therapy)			
10,355 participants; trial duration: 52 weeks			
symptomatic and ≥ 1 exacerbation in previous year $1 = 45\%$; $2 = 43\%$; $\ge 3 = 11\%$			
mean age 65; 34% women; 78% White			
35% current smokers; 65% former smokers			
ICS+LABA+LAMA	ICS+LABA		LAMA+LABA
fluticasone + vilanterol + umeclidinium			umeclidinium + vilanterol
moderate – severe exacerbations (annual rate)			
0.91	1.07		1.21
triple vs ICS+LABA ↓ 0.16 exacerbation per year rate ratio 0.85 (95%CI 0.80 to 0.90)		triple versus LAMA+LABA ↓ 0.30 exacerbation per year rate ratio 0.75 (95%CI 0.70 to 0.81)	
severe exacerbations (annual rate)			
0.13	0.15		0.19
		11	MPACT NEJM 2018;378:1671-1680

IMPACT 2018			
main publication: "efficacy and safety analyses were performed in the intention-to-treat population"			
appendix: "primary analysis of <u>on-treatment</u> moderate/severe			
COPD exacerbations"			
10,355 randomized			
7991 (77%)			
completed trial "on-treatment"			
IMPACT NEJM 2018;378:1671-1680			

IMPACT 2018 (triple vs. double combination therapy)			
10,355 participants; trial duration: 52 weeks			
symptomatic and ≥ 1 exacerbation in previous year $1 = 45\%$; $2 = 43\%$; $\ge 3 = 11\%$			
mean age 65; 34% women; 78% White			
35% current smokers; 65% former smokers			
ICS+LABA+LAMA	ICS+LABA		LAMA+LABA
fluticasone + vilanterol + umeclidinium			umeclidinium + vilanterol
SGRQ at baseline: 51 (score 0 to 100)			
45.0	46.8		46.8
triple vs ICS+LABA 1.8 point difference out of 100			erapy vs LAMA+LABA t difference out of 100
SGRQ improvement \geq 4 points out of 100			
42%	34%		34%
missing data: 20%	missing data: 27%		missing data: 29% MPACT NEJM 2018;378:1671-1680



IMPACT 2018 (triple vs. double combination therapy)				
10,355 participants; trial duration: 52 weeks				
symptomatic and ≥ 1 exacerbation in previous year 1 = 45%; 2 = 43%; $\geq 3 = 11\%$				
mean age 65; 34% women; 78% White				
35% current smokers; 65% former smokers				
ICS+LABA+LAMA	ICS+LABA	LAMA+LABA		
fluticasone + vilanterol + umeclidinium	fluticasone + vilanterol	umeclidinium + vilanterol		
people with serious adverse events (including COPD, pneumonia)				
22%	21%	23%		
	1	MPACT NEJM 2018;378:1671-1680		

Global Initiative for Chronic Obstructive Lung Disease GOLD **2016** guidelines

Have you noticed a difference since starting this treatment?

Are you less breathless? Can you do more? Can you sleep better?

Is that change worthwhile to you?

https://goldcopd.org/

Global Initiative for Chronic Obstructive Lung Disease GOLD 2018 guidelines

There is high quality evidence that ICS use is associated with oral candidiasis, hoarse voice, skin bruising and pneumonia

Patients at higher risk of pneumonia include: current smokers, age \geq 55, history of exacerbations or pneumonia, BMI < 25, poor dyspnea grade and/or severe airflow limitation

https://goldcopd.org/

budesonide + formoterol	100 mg/6 mcg	\$70 asthma
(Symbicort Turbuhaler)	200 mcg/6 mcg	\$95 COPD, asthma
fluticasone propionate + salmeterol	250 mcg/50 mcg	\$110 COPD, asthma
(Advair Diskus)	500 mcg/50 mcg	\$155 COPD, asthma
fluticasone furoate + vilanterol (Breo Ellipta)	100 mcg/25 mcg	\$90 COPD, asthma
	200 mcg/25 mcg	\$140 asthma
,		

BREO[®] ELLIPTA[®] 100'25 mcg once daily is the only strength indicated for the treatment of COPD. BREO[®] ELLIPTA[®] 200'25 mcg is not indicated for patients with COPD. There is no additional benefit of the 200'25 mcg dose compared to the 100'25 mcg dose and there is a potential increased risk of pneumonia and systemic corticosteroid-related adverse reactions.

https://health-products.canada.ca/dpd-bdpp/index-eng.jsp



